MIST - Milestone Pharma EV/EBITDA Multiple

Milestone Pharmaceuticals (MIST) ensures reliable cold-chain delivery of cardiac medications, mitigating customs risks to maintain high profitability. This price chart, featuring an EV/EBITDA metric of 0.00, illustrates the company during a period of intensive clinical trials for a high-demand heart rhythm control agent. The business's financial success is based on the market launch of innovative nasal sprays designed to curb tachycardia attacks.

MIST Milestone Pharmaceuticals Inc: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/10/2026

MIST (milestonepharma.com): analytical breakdowns and indicator data

- market price and analyst price targets:

Price Chart Milestone Pharma|MIST - Price Target Chart

- market capitalization statistics:

Market Capitalization Milestone Pharmaceuticals Inc|MIST - Total Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Milestone Pharmaceuticals|MIST - Book Valuation of Business|Market Cap to Net Assets Ratio milestonepharma.com|MIST - Aggregate Business Assets

- debt and liquidity data:

Debt to Equity Milestone Pharmaceuticals|MIST - Long-Term Liabilities to Capital|Short-Term Debt to Equity Milestone Pharmaceuticals Inc.|MIST - Company Aggregate Debt|Debts to Book Capitalization Milestone Pharmaceuticals Inc|MIST - Long-Term Debt|Company Current Liabilities Milestone Pharmaceuticals|Quick Liquidity milestonepharma.com

- business earnings and investment ratios data:

MIST - Profit After Tax|Projected Future Earnings Milestone Pharmaceuticals|MIST - Company Value to Net Income|Forward P/E Multiple Milestone Pharmaceuticals|MIST - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Milestone Pharmaceuticals Inc|MIST - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Milestone Pharmaceuticals|MIST - Net earnings per share for the last 12 months|Quarterly EPS earnings growth milestonepharma.com|MIST - Earnings growth in current year|Earnings growth forecast for next year Milestone Pharmaceuticals

Fundamental company valuation:Milestone Pharma MIST

Original product of Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals (MIST) is developing an emergency cardiac care system by introducing nasal sprays to treat tachycardia outside of clinical settings. An analysis of the company's current EV/EBITDA ratio allows for a comparison of the total enterprise value, including net debt, against its operating profit. This metric eliminates the impact of tax regimes and depreciation, revealing the actual efficiency of cash flow generation. A decline in this indicator confirms that assets are undervalued, creating an entry point for the long-term investor.

Competitor analysis